The U.S. Food and Drug Administration (FDA) announced the recall of anti-anxiety medication Xanax.
The recall is for 3 mg Xanax XR, the brand name for alprazolam. Affected items are in 60 tablet bottles.
The recall was voluntary and initiated on March 17, 2026.
More identifying factors:
It was recalled due to “Failed Dissolution Specifications,” according to the FDA. This means the drug fails to dissolve at the proper, tested rate within the body.
AARP explains that failed dissolution specifications mean “when the pill is swallowed, it may not break down at the right speed to be absorbed by the body. If it dissolves too slowly or unevenly, you might not get the full benefit — even if you take the correct dose.”
The FDA classified this as a Class II recall, meaning it could cause temporary or medically reversible health problems.
Class II recalls are “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
Xanax was distributed nationwide by Viatris Specialty LLC and made in Ireland.